Related Experiment Videos
Fatal, gold-induced pneumonitis
M Jose Soler1, Encarnacion Barroso, F Ignacio Aranda
1Servicio de Neumologia, Hospital General Universitario, Alicante, Spain.
Rheumatology International
|July 12, 2003
Summary
Gold sodium thiomalate therapy can cause irreversible interstitial pneumonitis. Early recognition and drug discontinuation are crucial for managing this adverse reaction.
Area of Science:
- Pulmonology
- Rheumatology
- Pharmacology
Background:
- Gold sodium thiomalate is a disease-modifying antirheumatic drug (DMARD) used in treating rheumatoid arthritis.
- Interstitial pneumonitis is a known, though typically reversible, adverse effect of gold therapy.
Observation:
- This report details a case of irreversible interstitial pneumonitis that developed during gold sodium thiomalate treatment.
- Analysis of factors potentially contributing to the unfavorable progression of this pharmacological reaction.
Findings:
- Irreversible interstitial pneumonitis can occur as a severe adverse event during gold sodium thiomalate therapy.
- Specific patient or treatment factors may influence the progression from a reversible to an irreversible state.
Implications:
- Emphasizes the critical need for early detection of interstitial pneumonitis in patients receiving gold sodium thiomalate.
- Highlights the importance of prompt drug cessation to mitigate severe, irreversible lung damage.